Roche presents new Phase III one-year data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss

Phase 3vamikibartPositive

AI Analysis

Summary

Roche presented one-year Phase III data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss. Specific efficacy and safety results were not detailed in the announcement.

Clinical Trial Data

Phase

Phase III

Outcome Details

One-year data presented

Importance:6/10

Sentiment:

0.50

Phase 3clinical dataophthalmologyvamikibartuveitic macular edema

Related Companies

$RHHBY

Read the original article

Published by yahoo_finance on October 10, 2026 9:40 PM

Read Original